Posts by calumd

Screenin3D microfluidic technology for cancer therapy assessment is published in the May issue of IEEE Open Journal of Engineering in Medicine and Biology

May 23rd, 2022 Posted by Uncategorized 0 thoughts on “Screenin3D microfluidic technology for cancer therapy assessment is published in the May issue of IEEE Open Journal of Engineering in Medicine and Biology”

“CAR-T cell development is expensive and patient-derived tissue is a limited resource. Our aim is to enable 20 to 50 times more experiments to be performed in these conditions.” – Dr M Zagnoni, CEO of Screenin3D

 

Miniaturisation and increased throughput in screening are key to a faster, more cost-effective delivery of cancer therapies from bench to bedside. In a new publication in IEEE Open Journal of Engineering in Medicine and Biology, Screenin3D OncoChip3D microfluidic platform was used to test the cytotoxicity of CAR-T cells and combination therapy on miniaturised solid cancer models.

In this publication, the technology showcases a co-culture of cancerous and stromal cells that create a physiologically relevant solid cancer model for the assessment of CAR-T, carboplatin, and anti-PD-L1 antibody therapies.

Read more about the application of OC3D Single microfluidic chip in the original publication and the EurekAlert press release 

Dr Zagnoni pitched at BioSeed 2022 early stages life sciences investment event

January 25th, 2022 Posted by Uncategorized 0 thoughts on “Dr Zagnoni pitched at BioSeed 2022 early stages life sciences investment event”

We are excited to announce that Screenin3D pitched at the BioSeed 2022 conference, a landmark investment event for early-stage companies featuring over 80 investors.

 

Dr Zagnoni presented a talk on CAR-T efficacy using our Screenin3D platform at the Festival of Biologics

November 11th, 2021 Posted by Events, News, PR 0 thoughts on “Dr Zagnoni presented a talk on CAR-T efficacy using our Screenin3D platform at the Festival of Biologics”

Screenin3D microfluidic technology is a game-changing approach for pre-clinical drug and therapy testing. At the Festival of Biologics in Basel, Dr Zagnoni presented a talk on our bespoke Onco-Chip3D technology used for the screening of combination immunotherapies with CAR-Ts and their off-target cytotoxicity.

ScreenIn3D to showcase new technology @ SLAS2020

January 21st, 2020 Posted by Events 0 thoughts on “ScreenIn3D to showcase new technology @ SLAS2020”

ScreenIn3D has been chosen to appear as an innovative company at SLAS2020 in San Diego.

 

 

Along with exhibiting, Michele Zagnoni will also be presenting our technology as part of the SLAS Ignite award. The SLAS Ignite Award recognizes the best start-up or emerging company exhibiting within Innovation AveNEW, a specially designated area within the exhibition.

Full details of the conference can be found on the SLAS website – https://www.slas2020.org/

You can also use the interactive floorplan to find where the ScreenIn3D booth will be located.

 

ELRIG Recognize ScreenIn3D’s Technical Innovation

November 28th, 2019 Posted by News, PR 0 thoughts on “ELRIG Recognize ScreenIn3D’s Technical Innovation”

ScreenIn3D has been awarded the prestigious ELRIG Prize for Innovation in Drug Discovery at their flagship conference Drug Discovery 2019 which recently took place in Liverpool, UK.

(more…)

Our Company
Follow Us

 

© Copyright ScreenIn3D. All rights reserved 2019.
ScreenIn3D Limited registered in Scotland. Registered number SC614453